pubmed.ncbi.nlm.nih.gov

EPMA position paper in cancer: current overview and future perspectives - PubMed

  • ️Thu Jan 01 2015

EPMA position paper in cancer: current overview and future perspectives

Godfrey Grech et al. EPMA J. 2015.

Abstract

At present, a radical shift in cancer treatment is occurring in terms of predictive, preventive, and personalized medicine (PPPM). Individual patients will participate in more aspects of their healthcare. During the development of PPPM, many rapid, specific, and sensitive new methods for earlier detection of cancer will result in more efficient management of the patient and hence a better quality of life. Coordination of the various activities among different healthcare professionals in primary, secondary, and tertiary care requires well-defined competencies, implementation of training and educational programs, sharing of data, and harmonized guidelines. In this position paper, the current knowledge to understand cancer predisposition and risk factors, the cellular biology of cancer, predictive markers and treatment outcome, the improvement in technologies in screening and diagnosis, and provision of better drug development solutions are discussed in the context of a better implementation of personalized medicine. Recognition of the major risk factors for cancer initiation is the key for preventive strategies (EPMA J. 4(1):6, 2013). Of interest, cancer predisposing syndromes in particular the monogenic subtypes that lead to cancer progression are well defined and one should focus on implementation strategies to identify individuals at risk to allow preventive measures and early screening/diagnosis. Implementation of such measures is disturbed by improper use of the data, with breach of data protection as one of the risks to be heavily controlled. Population screening requires in depth cost-benefit analysis to justify healthcare costs, and the parameters screened should provide information that allow an actionable and deliverable solution, for better healthcare provision.

Keywords: Biobank; Biomarker; Disease modeling; Expert recommendation; Individual profile; Multimodal diagnostics; Predictive preventive personalized medicine; Risk assessment; Screening; Standardization.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Worldwide incidence, mortality and 5 year prevalence in 2012. Data taken from GLOBOCAN [390] and prevalence data from [391].

Figure 2
Figure 2

Disease burden versus aid (adapted from [4]).

Similar articles

  • Tuberculosis.

    Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, Knight G, Murray M, Nardell E, Rubin E, Salomon J, Vassall A, Volchenkov G, White R, Wilson D, Yadav P. Bloom BR, et al. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. PMID: 30212088 Free Books & Documents. Review.

  • Dementia -- Caring, Ethics, Ethnical and Economical Aspects: A Systematic Review [Internet].

    Swedish Council on Health Technology Assessment. Swedish Council on Health Technology Assessment. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun. SBU Assessment No. 172. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun. SBU Assessment No. 172. PMID: 28876770 Free Books & Documents. Review.

  • Caution, "normal" BMI: health risks associated with potentially masked individual underweight-EPMA Position Paper 2021.

    Golubnitschaja O, Liskova A, Koklesova L, Samec M, Biringer K, Büsselberg D, Podbielska H, Kunin AA, Evsevyeva ME, Shapira N, Paul F, Erb C, Dietrich DE, Felbel D, Karabatsiakis A, Bubnov R, Polivka J, Polivka J Jr, Birkenbihl C, Fröhlich H, Hofmann-Apitius M, Kubatka P. Golubnitschaja O, et al. EPMA J. 2021 Aug 17;12(3):243-264. doi: 10.1007/s13167-021-00251-4. eCollection 2021 Sep. EPMA J. 2021. PMID: 34422142 Free PMC article.

  • Predictive, Preventive and Personalised Medicine as the hardcore of 'Horizon 2020': EPMA position paper.

    Golubnitschaja O, Kinkorova J, Costigliola V. Golubnitschaja O, et al. EPMA J. 2014 Apr 7;5(1):6. doi: 10.1186/1878-5085-5-6. EPMA J. 2014. PMID: 24708704 Free PMC article.

  • Digital biomarkers: 3PM approach revolutionizing chronic disease management - EPMA 2024 position.

    Smokovski I, Steinle N, Behnke A, Bhaskar SMM, Grech G, Richter K, Niklewski G, Birkenbihl C, Parini P, Andrews RJ, Bauchner H, Golubnitschaja O. Smokovski I, et al. EPMA J. 2024 May 11;15(2):149-162. doi: 10.1007/s13167-024-00364-6. eCollection 2024 Jun. EPMA J. 2024. PMID: 38841615 Free PMC article.

Cited by

References

    1. Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, et al. Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J. 2013;4(1):6. - PMC - PubMed
    1. Del Re M, Di Paolo A, van Schaik RH, Bocci G, Simi P, Falcone A, et al. Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? EPMA J. 2010;1(3):495–502. - PMC - PubMed
    1. World Health Organisation. Global status report on noncommunicable diseases 2010. http://whqlibdoc.who.int/publications/2011/9789240686458_eng.pdf?ua=1. Accessed 18 Jan 2014.
    1. Enserink M. After the windfall. Science. 2014;345(6202):1258–9. - PubMed
    1. Parry CD, Patra J, Rehm J. Alcohol consumption and non-communicable diseases: epidemiology and policy implications. Addiction. 2011;106(10):1718–24. - PMC - PubMed

LinkOut - more resources